Cancer Res 42:19942002 Imokawa G, Mishima Y (1984) Functional analysis of tyrosinase isozymes of cultured melanoma cells during the recovery period following interrupted melanogenesis induced by glycosylation inhibitors
Side effects can vary based on dose, frequency, product quality, medical history, medications, and individual response
Disclosures: Manasa Ginjupalli: Nothing to Disclose, Anuj Sharma: Nothing to Disclose, Fnu Vikash: Nothing to Disclose, Vikash Kumar: Nothing to Disclose, Gautam Maddineni: Nothing to Disclose, Arnold Nongmoh Forlemu: Nothing to Disclose, Jayalekshmi Jayakumar: Nothing to Disclose, Camelia Ciobanu: Nothing to Disclose, Ali Wakil: Nothing to Disclose, Amr Dokmak: Nothing to Disclose, Vijay Bhaskar Reddy Gayam: Nothing to Disclose, Praneeth Bandaru: Nothing to Disclose, Khalid Aloum: Nothing to Disclose, Raissa Nana Sede Mbakop: Nothing to Disclose, Lisnaldy Ramirez: Nothing to Disclose, Denzil Etienne: Nothing to Disclose, Madhavi Reddy: Nothing to Disclose 1913 MUTATED-Β- CATENIN DRIVES SUPPRESSION OF AN IMMUNE-REGULATORY MODULE OF TRANSCRIPTION FACTORS ALTERING EXPRESSION OF KEY CHEMOKINES INVOLVED IN IMMUNE RESPONSE IN HEPATOCELLULAR CANCERS Brandon Lehrich 1 Junyan Tao 1 Evan Delgado 1 Catherine Cao 1 Tyler Yasaka 1 Yuqing Liu 1 Minakshi Poddar 1 Sucha Singh 1 Xiangnan Guan 2 Hartmut Koeppen 2 Silvia Liu 1 Yulei Wang 2 Satdarshan (Paul) Monga 1 , 1 University of Pittsburgh, 2 Translational Medicine, Genentech Inc., San Francisco, CA, USA Background: Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related mortality worldwide
In its inactive state, ASK1 binds to reduced thioredoxin (TRX), which can be oxidized by H 2 O 2 , resulting in the dissociation and subsequent activation of ASK1
doi: 10.1016/s0092-8674(03)00154-5
